Mb, Levis & Associates, LLC Exelixis, Inc. Transaction History
Mb, Levis & Associates, LLC
- $215 Billion
- Q1 2025
A detailed history of Mb, Levis & Associates, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Mb, Levis & Associates, LLC holds 1,000 shares of EXEL stock, worth $45,720. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,000
Previous 1,000
-0.0%
Holding current value
$45,720
Previous $33.3 Million
10.87%
% of portfolio
0.02%
Previous 0.02%
Shares
3 transactions
Others Institutions Holding EXEL
# of Institutions
613Shares Held
257MCall Options Held
1.57MPut Options Held
730K-
Black Rock Inc. New York, NY33.5MShares$1.53 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA28.7MShares$1.31 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA22.5MShares$1.03 Billion4.78% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny14.8MShares$678 Million0.88% of portfolio
-
State Street Corp Boston, MA11.8MShares$539 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $14.7B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...